Just reported
From P3 Health Partners's results release of 2026年11月9日; its quarterly report has since been filed.
Actual
US$396.3M
+15% y/y
+2.6% q/q
Guided
—
No guide given
Actual
US$0.07
-97% q/q
Guided
—
No guide given
Actual
US$23M
-44% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes P3 Health Partners is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
基于 P3 Health Partners Inc. 自己向美国证券交易委员会(SEC)提交的申报文件。数字如实呈报,每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议,也不是买卖任何证券的推荐。
US$2.55-7.3%11月13日 收盘
数据截至2026年9月30日,来自2026年11月9日提交的10-Q
Grade D
价格下方的色带显示每个日期的评级,仅依据当时已公开的文件计算。
显示 P3 Health Partners Inc. 评级历史 16 个季度中的 2 个。 其余 14 个可回溯到 2023年3月。